Phase I/II Trial of Carboplatin and Paclitaxel Chemotherapy in Combination with Intravenous Oncolytic Reovirus in Patients with Advanced Malignancies
| Autor: | Mercel Ball, James Larkin, Katie Twigger, Katie L. Newbold, Victoria Roulstone, Kevin J. Harrington, Alan Melcher, K. Mettinger, Brad Thompson, Geoffrey D. Hall, Mary Anne Lagmay Tanay, Hardev Pandha, Martin Gore, Matthew C. Coffey, John D. Chester, Kostas N. Syrigos, Eleni M. Karapanagiotou, Christopher M. Nutting, Richard G. Vile |
|---|---|
| Rok vydání: | 2012 |
| Předmět: |
Adult
Diarrhea Male Oncology Cancer Research medicine.medical_specialty Paclitaxel medicine.medical_treatment Phases of clinical research Drug Administration Schedule Article Carboplatin chemistry.chemical_compound Neoplasms Internal medicine Antineoplastic Combined Chemotherapy Protocols Reolysin medicine Humans Mammalian orthoreovirus 3 Aged Oncolytic Virotherapy Stomatitis Chemotherapy Dose-Response Relationship Drug business.industry Head and neck cancer Cancer Nausea Middle Aged medicine.disease Combined Modality Therapy Surgery Oncolytic Viruses Treatment Outcome chemistry Head and Neck Neoplasms Response Evaluation Criteria in Solid Tumors Area Under Curve Disease Progression Female business |
| Zdroj: | Clinical Cancer Research. 18:2080-2089 |
| ISSN: | 1557-3265 1078-0432 |
| DOI: | 10.1158/1078-0432.ccr-11-2181 |
| Popis: | Purpose: Reovirus type 3 Dearing (RT3D) replicates preferentially in Ras-activated cancers. RT3D shows synergistic in vitro cytotoxicity in combination with platins and taxanes. The purpose of this phase I/II study was to assess RT3D combined with carboplatin/paclitaxel in patients with advanced cancers. Experimental Design: Patients were initially treated in a dose-escalating, phase I trial with intravenous RT3D days 1 to 5, carboplatin [area under curve (AUC) 5, day 1] and paclitaxel (175 mg/m2, day 1) 3-weekly. RT3D was escalated through three dose levels: 3 × 109, 1 × 1010, and 3 × 1010 TCID50 in cohorts of three. Primary endpoints were to define the maximum tolerated dose and dose-limiting toxicity and to recommend a dose for phase II studies. Secondary endpoints included pharmacokinetics, immune response, and antitumor activity. A subsequent phase II study using the 3 × 1010 TCID50 dose characterized the response rate in patients with head and neck cancer. Results: Thirty-one heavily pretreated patients received study therapy. There were no dose-limiting toxicities during dose-escalation and most toxicities were grade I/II. Overall effectiveness rates were as follows: one patient had a complete response (3.8%), six patients (23.1%) had partial response, two patients (7.6%) had major clinical responses clinically evaluated in radiation pretreated lesions which are not evaluable by Response Evaluation Criteria in Solid Tumors (RECIST), nine patients (34.6%) had stable disease, and eight patients (30.8%) had disease progression. Viral shedding was minimal and antiviral immune responses were attenuated compared with previous single-agent data for RT3D. Conclusions: The combination of RT3D plus carboplatin/paclitaxel is well tolerated with evidence of activity in cancer of the head and neck. A randomized phase III study is currently open for recruitment. Clin Cancer Res; 18(7); 2080–9. ©2012 AACR. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|